Would you offer the PACIFIC protocol to a patient with stage III lung cancer with performance status 2-3?
If so, how would you modify this regimen?
Community PollStarted
How do you manage stage III NSCLC patients with a performance status of 2-3?
155 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Cedars-Sinai Medical Center
Answered on
The PACIFIC trial did not evaluate this regimen in patients with performance status 2-3. Durvalumab dosing does not change based on toxicity. I do not use this regimen for patients with PS 2-3 without supporting data at this time.
Join for free or sign in to see the full answer